Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.
Caroline Emilie B ThomsenT F HansenR F AndersenJ LindebjergL H JensenA JakobsenPublished in: Journal of experimental & clinical cancer research : CR (2018)
The results indicate that the ctDNA level holds potential as a clinically valuable marker in first line treatment of mCRC. A rapid decrease was associated with a prolonged progression free interval, whereas a significant increase gave notice of early progression with a relevant lead time.